Since the up-regulation of VEGFR-2 is pronounced in malignant tumors, VEGFR-2 inhibitors have proved their profound anti-proliferative activities in many tumors, including pancreatic [7,8] and hepatocellular cancers [9,10]. Here, KDR is linked to hepatocellular carcinoma.